Drug Trial Radar · NCT06176040
A Study of TAVO101 in Atopic Dermatitis Patients
Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 15, 2024
Primary completion
Mar 15, 2025
Study completion Jun 15, 2025
Sponsor
- Lead sponsor
- Tavotek BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
Conditions
- Atopic Dermatitis
Interventions
TAVO101Drug
TAVO101 IV Infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients who achieve a 50% Reduction From Baseline in Eczema Area and Severity (EASI 50) at Week 16Time frame: Baseline to Week 16
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Royal Melbourne Hospital
Parkville, Victoria, Australia
Optimal Clinical Trials
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.